A method for establishing a mouse model of progressive retinal degeneration

Through CRISPR/Cas9 gene editing technology, the Phb2 gene was knocked out in retinal photoreceptor cells, and the RKO mouse model was constructed, which solved the problem that the progress of the existing mouse model did not conform to clinical laws, and achieved a gradual approach suitable for studying retinal degeneration diseases. Sex model simulates the onset of retinal degeneration disease in clinical practice and saves research resources.

CN118383330BActive Publication Date: 2024-11-01ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410459712.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-17
Publication Date
2024-11-01
Estimated Expiration
2044-04-17

AI Technical Summary

Technical Problem

The existing mouse models of retinal degeneration disease (such as rd1, rd7, rd9, rd10) progress too fast or too slowly, which is not suitable for simulating the progressive disease process of clinical patients, and the onset age is not appropriate, making it difficult to conduct effective experiments. Research.

Method used

The RKO mouse model was constructed by CRISPR/Cas9 gene editing technology. The model showed early retinal degeneration at 6 weeks old, significantly thinning at 10 weeks old, and at 16 weeks old. The retinal photoreceptor cells were completely degenerated, simulating the pathogenesis of progressive retinal degeneration.

Benefits of technology

The RKO mouse model can gradually show the typical characteristics of retinal degeneration disease within 10 weeks, with a moderate onset age, which is easy to observe changes in the disease and evaluate the efficacy, save time and resources, and is suitable as an ideal experimental animal model.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118383330B_ABST
    Figure CN118383330B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for establishing a mouse model of progressive retinal degenerative disease. The mouse model is obtained by specifically knocking out the Phb2 gene in retinal photoreceptor cells and is named RKO mouse. The RKO mouse constructed by the present invention is similar to the pathogenesis of retinal degenerative diseases in clinical practice, that is, the disease progresses progressively. The different stages of disease progression can be detected using existing inspection methods, which is convenient for observing the effects of intervention measures. The onset age of RKO mice is moderate, and the model is an ideal experimental animal model for studying retinal degenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a method for establishing a mouse model of progressive retinal degeneration. Background Art

[0002] Retinal degeneration (RD) is a group of fundus diseases caused by inherited or acquired causes, which are structural or functional abnormalities of retinal photoreceptor cells and retinal pigment epithelial cells, including age-related macular degeneration (AMD), retinitis pigmentosa (RP), Stargardt disease (STGD), etc., and are the most common neurodegenerative diseases in the world. These diseases have a great impact on visual function, often leading to night blindness, reduced visual field and irreversible loss of vision, but their pathogenesis is not yet fully understood, and there is no effective prevention and treatment in clinical practice, so a lot of research is still needed for these diseases.

[0003] It is very important to study the pathogenesis of such diseases and explore possible treatment options with the help of ideal experimental animal models. Currently, the commonly used retinal degeneration model mice include rd1, rd7, rd9 and rd10. However, these model mice still have certain limitations.

[0004] One of the main pathological changes in RD is the thinning of the outer retina, especially the outer nuclear layer. Photoreceptor cells are mainly distributed in the outer retina, including the photoreceptor cell layer (inner segments, outer segments), outer nuclear layer (nuclei), and outer plexiform layer (synapses). During the onset of RD, as photoreceptor cells gradually die, the number of nuclei gradually decreases, and the outer nuclear layer gradually becomes thinner. Therefore, in terms of retinal structure, the disease progression of RD model mice can be evaluated by evaluating the retinal thickness, especially the outer retinal thickness or the outer nuclear layer thickness.

[0005] One of the main clinical manifestations of RD is the gradually worsening visual dysfunction. Electroretinogram (ERG) is often used in clinical practice to assist in the diagnosis of RD. Therefore, in terms of retinal function, ERG can be used to evaluate the disease progression of RD model mice.

[0006] Combining the two evaluation criteria of retinal thickness (outer nuclear layer thickness) and ERG, the disease progression of rd1 model mice and rd10 model mice was too rapid. When the rd1 model mice opened their eyes (13 days after birth), the thickness of the outer retina decreased by 73%, and the outer retina could no longer be distinguished on the 20th day after birth; from the perspective of visual function, ERG waveforms could not be detected in rd1 model mice of any age. The retinal thickness of rd10 model mice gradually became thinner after birth, especially the outer nuclear layer, which could no longer be detected on the 9th week after birth; from the perspective of visual function, the amplitude of ERG light-dark adaptation waveforms of rd10 model mice decreased to 50% and 30% respectively on the 18th day after birth compared with the control mice, and decreased to 30% and 10% respectively on the 30th day after birth, and the ERG waveform completely disappeared on the 50th day after birth. The disease progression of rd1 model mice and rd10 model mice was rapid, which was different from the gradual progression of such diseases in clinical practice. In addition, the disease progresses rapidly in the model mice, making it difficult to administer intervention measures and observe therapeutic effects. Therefore, the rd1 model mice and rd10 model mice are not the most ideal experimental animal models for studying such diseases.

[0007] Combining the two evaluation criteria of retinal thickness (outer nuclear layer thickness) and ERG, the rd7 model mice and rd9 model mice have an older age of onset and the disease progresses too slowly. The number of nuclei in the outer nuclear layer of the rd7 model mice began to gradually decrease at 16 months after birth, from about 10 layers to about 4-5 layers; from the perspective of visual function, the ERG amplitude only decreased by 50% at 16 months after birth. The thickness of the outer nuclear layer of the retina of the rd9 mice decreased compared with the control mice at 12 months after birth, and the thickness of the outer nuclear layer continued to decrease slowly until 18 months after birth; from the perspective of visual function, the ERG amplitude gradually decreased from 12 months after birth. The rd7 model mice and rd9 model mice have an older age of onset and a slower disease progression. It takes a lot of time and manpower and material resources to conduct experiments with them, so they are not the most ideal experimental animal models for studying such diseases.

[0008] In summary, an ideal retinal degeneration model mouse is one that can simulate the disease process of clinical patients to the greatest extent possible, that is, the disease progresses gradually, retinal photoreceptor cells progressively die, the different stages of disease progression can be monitored through currently available examination methods, and light damage as a risk factor can accelerate disease progression. In addition, the onset age of the model mouse should not be too old. Summary of the invention

[0009] The present invention aims at providing a method for establishing a mouse model of progressive retinal degenerative diseases, in view of the fact that the currently commonly used mouse models (rd1, rd7, rd9, rd10) for studying retinal degenerative diseases still have certain limitations and are not the most ideal experimental animal models. The RKO mouse model constructed by this method is similar to the pathogenesis of retinal degenerative diseases in clinic, and the onset age of RKO mice is moderate, so it is a relatively ideal experimental animal model for studying retinal degenerative diseases.

[0010] The objective of the present invention is achieved through the following technical solutions:

[0011] A method for establishing a mouse model of progressive retinal degenerative disease is obtained by specifically knocking out the Phb2 gene (Gene ID: 11331) in retinal photoreceptor cells, and specifically comprises the following steps:

[0012] S1. CRISPR / Cas9 gene editing technology was used to insert LoxP sites into the Phb2 gene of C57BL / 6J wild-type mice to construct Phb2 flox / flox Mice;

[0013] S2, Phb2 flox / flox Phb2 was obtained by crossing mice with commercial Rho-Cre mice. flox / + ;Rho-Cre mice;

[0014] S3, Phb2 flox / + ; Rho-Cre mice were self-bred to obtain the target gene mouse Phb2 flox / flox ; Rho-Cre mice, named RKO mice.

[0015] Further, step S1 is specifically as follows: using CRISPR / Cas9 gene editing technology, a LoxP site in the same direction is inserted at both ends of the upstream and downstream of the fourth exon region of the Phb2 gene of wild-type (WT) mice with a C57BL / 6J background to obtain Phb2 flox / + Mouse, Phb2 flox / + The mice were further selfed to obtain Phb2 flox / flox Mouse.

[0016] The present invention also provides the application of the method for establishing the progressive retinal degenerative disease mouse model in the field of animal model construction. Preferably, the animal model construction refers to the construction of a progressive retinal degenerative disease mouse model.

[0017] The present invention also provides the use of the progressive retinal degeneration mouse model obtained by the method for establishing the progressive retinal degeneration mouse model in retinal degeneration disease research, wherein the research is for the purpose of non-disease diagnosis or treatment.

[0018] The present invention also provides the use of the progressive retinal degenerative disease mouse model obtained by the method for establishing the progressive retinal degenerative disease mouse model in screening drugs for preventing or treating retinal degenerative diseases.

[0019] The present invention also provides a method for screening candidate drugs for preventing or treating retinal degenerative diseases, comprising the step of administering the test candidate drug to the progressive retinal degenerative disease mouse model obtained according to the above-mentioned establishment method.

[0020] With the help of CRISPR / Cas9 gene editing technology, our team invented a new retinal degeneration model mouse. By specifically knocking out the Phb2 gene in retinal photoreceptor cells, a new genetically engineered mouse was obtained, named RKO mouse.

[0021] RKO mice showed early RD phenotype at 6 weeks of age. At 6 weeks of age, there were no obvious abnormalities in retinal structure and function, and only apoptosis of photoreceptor cells was observed at the edge of the retina, that is, mild retinal degeneration.

[0022] RKO mice showed obvious RD phenotype at 10 weeks of age. At 10 weeks of age, the retina was significantly thinner, especially the outer nuclear layer; from the perspective of visual function, the amplitude of ERG light and dark adaptation decreased, and the decrease in dark adaptation amplitude was more obvious than that of light adaptation, which suggested that rod cells were more severely damaged than cone cells, which is consistent with the clinical rule that rod cells are affected first.

[0023] At 16 weeks of age, the retinal photoreceptor cells of RKO mice completely degenerate and disappear. At 16 weeks of age, the retina is severely thinned, especially the outer retina is significantly thinner and the structure is disordered and difficult to identify. The outer nuclear layer is almost completely gone, while the inner retina is clearly layered and intact. In terms of visual function, ERG light and dark adaptation is almost completely gone.

[0024] In summary, RKO mice, a new type of retinal degeneration model mouse, can better simulate the phenotype of progressive retinal degeneration in adult mice. Specifically, they show early mild retinal degeneration at 6 weeks of age, but do not cause serious damage to the retinal structure and function. RKO mice show severe structural and functional changes at 10 weeks of age, and almost completely lose visual function and photoreceptor cell layer at 16 weeks of age, providing an ideal animal model for retinal degeneration research.

[0025] The present invention has the following beneficial effects:

[0026] 1. RKO mice show a progressive onset of disease, which lasts for 10 weeks from onset to complete degeneration of retinal photoreceptor cells. Light damage can accelerate the progression of the disease, which is similar to the pathogenesis of retinal degenerative diseases in clinical practice. Compared with other model mice, it better simulates the pathogenesis of such diseases.

[0027] 2. RKO mice are convenient for continuous observation of the progression of retinal degenerative diseases, easy to administer intervention measures and observe the therapeutic effects, and are a more ideal experimental animal model for studying retinal degenerative diseases.

[0028] 3. The onset age of RKO mice is about 6 weeks, which is moderate compared with other model mice. Mice in this age group have better physical functions and can tolerate multiple general anesthesia and experimental operations, which facilitates continuous observation of phenotypes.

[0029] 4. RKO mice develop the disease at 6 weeks of age, which saves a lot of time, manpower, material and financial resources compared to other model mice that need to be raised until 12 months of age before developing the disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Construction scheme for RKO mice.

[0031] Figure 2 The results of the LoxP site genotype identification of Phb2 in RKO mice and control mice. Ctrl refers to Phb2 flox / flox Mice, wt refers to wild-type mice on a C57BL / 6J background.

[0032] Figure 3 Retinal thickness and visual function of 6-week-old RKO mice and Ctrl control mice.

[0033] Figure 4 Retinal thickness and visual function of 10-week-old RKO mice and Ctrl control mice.

[0034] Figure 5 Retinal thickness and visual function of 16-week-old RKO mice and Ctrl control mice. DETAILED DESCRIPTION

[0035] In order to make the technical problem and technical solution to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0036] The construction scheme of the RKO mouse of the present invention is as follows Figure 1 shown.

[0037] Example 1 Construction of RKO mouse model

[0038] (1) CRISPR / Cas9 gene editing technology was used to insert a LoxP site in the same direction at both ends of the upstream and downstream of the fourth exon region of the Phb2 gene in wild-type (WT) mice with a C57BL / 6J background to obtain Phb2 flox / + Mouse, Phb2 flox / + The mice were further selfed to obtain Phb2 flox / flox Mice;

[0039] (2) Phb2 flox / flox Phb2 was obtained by crossing mice with commercial Rho-Cre mice. flox / + ;Rho-Cre mice;

[0040] (3) Phb2 flox / + ; Rho-Cre mice were self-bred to obtain the target gene mouse Phb2 flox / flox ; Rho-Cre mice, named RKO mice.

[0041] Example 2 Identification of RKO Mouse Genotype

[0042] 1. DNA extraction from mouse tail tissue:

[0043] 1) Take out and restrain the mice to be identified, number them by clipping their toes, cut 0.5 cm of the mouse tail that has been wiped thoroughly with alcohol, put it in a 1.5 mL sterilized EP tube, and mark the mouse number and breeding cage number;

[0044] 2) Place the EP tube containing the mouse tail into a centrifuge and centrifuge (room temperature, 1000 g, 1 min) to centrifuge the mouse tail tissue to the bottom of the EP tube;

[0045] 3) Add 100 μL of 50 mM sodium hydroxide aqueous solution to each EP tube, and after the lysed tissue is suspended, lyse in a 95°C metal bath for 10 minutes. After lysis, centrifuge at low speed to collect the liquid on the tube cap and tube wall at the bottom of the tube;

[0046] 4) Add 10 μL of 1M Tris-HCl balanced solution (pH=8.0) to each tube, centrifuge (room temperature, 1000 g, 1 min), then add 100 μL of ddH2O and centrifuge at a low speed for a short time to obtain the extracted mouse DNA.

[0047] 2. Mouse genotype identification:

[0048] 1) The PCR reaction system is as follows:

[0049]

[0050] 2) The PCR reaction procedure is as follows:

[0051]

[0052] 3) Agarose gel electrophoresis:

[0053] After the PCR reaction is completed, weigh 2g of agarose powder into a 250mL conical flask, pour in 100mL 1X TAE, seal the conical flask with aluminum foil, place in a microwave and heat until boiling, shake gently and heat again until the colloidal liquid is uniform, wait for it to cool slightly, add GelStain solution at 1:10000, shake gently to mix, and then pour into the gel making tank with the gel comb inserted, be careful not to have bubbles. Let it stand at room temperature for 30 minutes, pull out the gel comb after the agarose gel is completely solidified, and insert the gel into the electrophoresis tank filled with fresh TAE. Take 5μL of PCR product, add it to the agarose gel comb hole, electrophoresed at 150V for 30 minutes, and take out the agarose gel to detect whether there is a target band in the PCR product.

[0054] 4) The primer sequences for mouse genotype identification are as follows:

[0055]

[0056] 5) The results of genotyping of the LoxP sites of Phb2 are shown in Figure 2 .

[0057] Depend on Figure 2 It can be seen that compared with wt mice, Ctrl and RKO mice showed a single band of 252 bp under the amplification conditions of Phb2 primers, while wt mice showed a single band of 163 bp.

[0058] Example 3 Detection of relevant indicators of RKO mice

[0059] RKO mice and Ctrl mice (Phb2 flox / flox The retinal thickness and visual function of mice at 6, 10, and 16 weeks of age were tested as follows:

[0060] 1. Retinal thickness detection

[0061] The mouse retina was examined using the OCT module of the Small Animal Retinal Imaging System (Phoenix) as follows:

[0062] (1) Anesthesia: Intraperitoneal injection of 1% sodium pentobarbital (dose 70 mg / kg);

[0063] (2) Mydriasis and local anesthesia: After the mouse is anesthetized for about 3-5 minutes, compound tropicamide eye drops (mydriatic drug) and alcaine eye drops (topical anesthetic) are instilled into both eyes to dilate the pupil and perform local anesthesia.

[0064] (3) After the pupil is completely dilated (about 5 minutes), place the mouse on the small animal retinal imaging system mouse holder to expose the eyeball;

[0065] (4) Open the OCT scanning software and perform a whole-retina scan. During the OCT scanning process, 0.9% saline was dripped onto the ocular surface to keep the mouse ocular surface moist;

[0066] (5) Then adjust the position of the mouse so that the center of the optic disc is located in the center of the scanning area;

[0067] (6) Scan the mouse retina horizontally with the optic disc as the center to collect images;

[0068] (7) Save the scanned image data and use the OCT built-in software to export the retinal OCT image;

[0069] (8) Use OCT software to calculate the total retinal thickness, count and plot.

[0070] 2. HE staining of retinal tissue

[0071] (1) Dewaxing: Paraffin sections stored at room temperature were placed in a 60°C oven for 30 minutes, and then placed in xylene to remove the paraffin from the sections. The sections were immersed in xylene (I, II, III) three times, each time for 10 minutes.

[0072] (2) Hydration (rehydration): After dewaxing, the sections were rehydrated in a gradient of alcohols, in order: 100% alcohol (I) for 5 min, 100% alcohol (II) for 5 min, 90% alcohol for 3 min, 70% alcohol for 3 min, 30% alcohol for 3 min, and finally rinsed in tap water for 1 min;

[0073] (3) Hematoxylin staining: After rehydration, the sections were placed in hematoxylin staining solution for 2-3 minutes, then soaked in pure water for 1 minute, and then differentiated with 1% hydrochloric acid ethanol for 3 seconds to make the staining of the cell nucleus and cytoplasm clearer, and then immediately rinsed slowly with running water for 10 minutes;

[0074] (4) Eosin staining: The sections were immersed in eosin stain for 1-2 min and then washed with tap water for 1 min.

[0075] (5) Dehydration: The stained sections were dehydrated again by soaking in 95% alcohol (I) for 30 seconds, 95% alcohol (II) for 30 seconds, 100% alcohol (I) for 1 minute, and 100% alcohol (II) for 1 minute.

[0076] (6) Transparency: After dehydration, the sections were treated with xylene for transparency. The sections were immersed in xylene three times (I, II, III), each time for 10 min.

[0077] (7) Sealing: Lay the transparent slice flat, wipe the remaining liquid with a cotton swab, add a drop of neutral gum on the slice, and then cover it with a cover glass to seal (avoid bubbles). Leave it at room temperature for about half an hour, and when the gum is slightly dry, it can be stored or filmed.

[0078] 3. Visual function test

[0079] The mouse electroretinogram (ERG) was recorded using the Diagnosys Celeris rodent ERG device. All mice prepared for electrophysiological testing were dark-adapted overnight in advance. The specific steps are as follows:

[0080] (1) Anesthesia: Intraperitoneal injection of 1% sodium pentobarbital (dose 70 mg / kg);

[0081] (2) Mydriasis and local anesthesia: After the mouse is anesthetized for about 3-5 minutes, compound tropicamide eye drops (mydriatic drug) and alcaine eye drops (topical anesthetic) are instilled into both eyes to dilate the pupil and perform local anesthesia.

[0082] (3) After the pupil is completely dilated (about 5 minutes), place the mouse on the Diagnosys Celeris instrument warming table (maintain the mouse body temperature at 37°C). Add a small amount of normal saline to the eye surface to keep the eye surface moist;

[0083] (4) During the ERG experiment, the mice were kept away from light. First, the mice were subjected to a dark adaptation test. In the dark adaptation procedure, the stimulus light was white light, and the stimulus light intensity was 0.01 cd·s / m 2 、0.1cd·s / m 2 , 1cd·s / m 2 、10cd·s / m 2 , record the electroretinogram responses (a-wave and b-wave) of mice;

[0084] (5) The mice that completed dark-adapted ERG were light-adapted for 5 minutes. After 5 minutes, the light-adapted ERG structure was detected by light stimulation. The stimulation light intensity was 3 cd·s / m 2 、10cd·s / m 2 、30cd·s / m 2 , the electroretinogram responses (b waves) of mice were recorded.

[0085] Results Figure 3-5 shown.

[0086] Depend on Figure 3 It can be seen that RKO mice showed early RD phenotype at 6 weeks of age. At 6 weeks of age, there were no obvious abnormalities in retinal structure and function, and only apoptosis of photoreceptor cells was observed at the edge of the retina, that is, mild retinal degeneration.

[0087] Depend on Figure 4 It can be seen that RKO mice showed obvious RD phenotype at 10 weeks of age. At 10 weeks of age, the retina was significantly thinner, especially the outer nuclear layer; from the perspective of visual function, the amplitude of ERG light and dark adaptation decreased, and the decrease in dark adaptation amplitude was more obvious than light adaptation, which suggests that rod cells are more severely damaged than cone cells, which is consistent with the clinical rule that rod cells are affected first.

[0088] Depend on Figure 5 It can be seen that the retinal photoreceptor cells of RKO mice completely degenerate and disappear at 16 weeks of age. At 16 weeks of age, the retina is severely thinned, especially the outer retina is significantly thinner and the structure is disordered and difficult to identify. The outer nuclear layer is almost completely gone, while the inner retina is clearly layered and intact. From the perspective of visual function, ERG light and dark adaptation is almost completely gone.

[0089] The above detailed description is a specific description of the possible embodiments of the present invention. The embodiments are not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not deviate from the present invention should be included in the patent scope of this case.

Claims

1. A method for establishing a mouse model of progressive retinal degeneration, characterized in that: It is obtained by specifically knocking out the Phb2 gene in retinal photoreceptor cells.

2. The method for establishing a mouse model of progressive retinal degeneration according to claim 1, characterized in that: The following steps are involved: S1. CRISPR / Cas9 gene editing technology was used to insert Loxp sites into the Phb2 gene of C57BL / 6J wild-type mice to construct Phb2 flox / flox Mice; S2, Phb2 flox / flox Phb2 was obtained by crossing mice with commercial Rho-Cre mice. flox / + ;Rho-Cre mice; S3, Phb2 flox / + ; Rho-Cre mice were self-bred to obtain the target gene mouse Phb2 flox / flox ; Rho-Cre mice, named RKO mice.

3. The method for establishing a mouse model of progressive retinal degeneration according to claim 2, characterized in that: step S1 specifically involves inserting a LoxP site in the same direction at both ends of the upstream and downstream of the fourth exon region of the Phb2 gene of C57BL / 6J wild-type mice using CRISPR / Cas9 gene editing technology to obtain Phb2 flox / + Mouse, Phb2 flox / + The mice were further selfed to obtain Phb2 flox / flox Mouse.

4. Application of the establishment method according to any one of claims 1 to 3 in the field of animal model construction.

5. The use according to claim 4, characterized in that: The animal model is a progressive retinal degeneration disease mouse model.

6. Use of the progressive retinal degenerative disease mouse model obtained by the establishment method according to any one of claims 1 to 3 in the study of retinal degenerative diseases, wherein the purpose of the study is non-disease diagnosis or treatment.

7. Use of the progressive retinal degenerative disease mouse model obtained by the establishment method according to any one of claims 1 to 3 in screening drugs for preventing or treating retinal degenerative diseases.

8. A method for screening candidate drugs for preventing or treating retinal degenerative diseases, characterized in that: The method comprises the step of administering a test candidate drug to the progressive retinal degeneration disease mouse model obtained by the establishment method according to any one of claims 1 to 3.